nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.09.2013 | short review

ASH 2012 update chronic lymphocytic leukemia—the best is yet to come

verfasst von: Lukas Weiss, Thomas Melchardt, Richard Greil, Georg Hopfinger

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Treatment of CLL has been significantly improved through combination of chemotherapy and rituximab. Furthermore, the positive influence of MRD negativity on survival was clearly demonstrated. More recently, drugs with novel modes of action, e.g. targeting B-cell receptor or downstream, chemotherapy-free therapy concepts seem to possible in the near future. More importantly, administration of new drugs with the aim to overcome unfavorable prognostic factors as 17p- or BIRC3, NOTCH1 and SF3B1 is warranted.

Vorheriger Artikel ASH 2012: allogeneic stem cell transplantation

Nächster Artikel Philadelphia-negative myeloproliferative neoplasms at the 2012 ASH meeting: a personal summary

Landau D-A, Carter S, Stojanov P, Stevenson KE, Mckenna A, Lawrence M, et al. The evolution and impact of subclonal mutations in chronic lymphocytic leukemia. ASH Annual Meeting Abstracts. 2012;120(21):5.

Rossi D, Rasi S, Spina V, Bruscaggin A, Monti S, Ciardullo C, et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. ASH Annual Meeting Abstracts. 2012;120(21):712.

Wu CJ. Understanding the role of mutations in SF3B1 and splicing in chronic lymphocytic leukemia. ASH Annual Meeting Abstracts. 2012;120(21):SCI–S15.

Byrd JC, Furman RR, Coutre S, Flinn IW, Burger JA, Blum KA, et al. The Bruton’s tyrosine kinase (BTK) inhibitor Ibrutinib (PCI-32765) promotes high response rate, durable remissions, and is tolerable in treatment naive (TN) and relapsed or refractory (RR) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients including patients with high-risk (HR) disease: new and updated results of 116 patients in a phase Ib/II study. ASH Annual Meeting Abstracts. 2012;120(21):189.

Burger JA, Keating MJ, Wierda WG, Hoellenriegel J, Ferrajoli A, Faderl S, et al. The BTK inhibitor ibrutinib (PCI-32765) in combination with rituximab is well tolerated and displays profound activity in high-risk chronic lymphocytic leukemia (CLL) patients. ASH Annual Meeting Abstracts. 2012;120(21):187.

Coutre SE, Leonard JP, Furman RR, Barrientos JC, de Vos S, Flinn IW, et al. Combinations of the selective phosphatidylinositol 3-kinase-delta (PI3Kdelta) inhibitor GS-1101 (CAL-101) with rituximab and/or bendamustine are tolerable and highly active in patients with relapsed or refractory chronic lymphocytic leukemia (CLL): results from a phase I study. ASH Annual Meeting Abstracts. 2012;120(21):191.

Porter DL, Grupp SA, Kalos M, Loren AW, Lledo L, Gilmore J, et al. Chimeric antigen receptor t cells directed against CD19 induce durable responses and transient cytokine release syndrome in relapsed, refractory CLL and ALL. ASH Annual Meeting Abstracts. 2012;120(21):717.

Assouline S, Buccheri V, Delmer A, Doelken G, Gaidano G, McIntyre C, et al. Subcutaneous rituximab in combination with fludarabine and cyclophosphamide for patients with CLL: initial results of a phase Ib study (SAWYER [BO25341]) show non-inferior pharmacokinetics and comparable safety to that of intravenous rituximab. ASH Annual Meeting Abstracts. 2012;120(21):1637.

Flinn IW, Harwin WN, Ward P, Doss HH, Papish SW, Hainsworth JD, et al. Phase II trial of ofatumumab (OFA) for older patients and patients who refuse fludarabine-based regimens with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ASH Annual Meeting Abstracts. 2012;120(21):719.

10.

Ferrajoli A, Falchi L, O’Brien S, Wierda W, Faderl S, Smith SC, et al. Combination of ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL): results of a phase II trial. ASH Annual Meeting Abstracts. 2012;120(21):720.

11.

Kalaycio M, Negrea OG, Elstrom R, Farber C, Horne H, Wegener WA, et al. Monotherapy with subcutaneous (SC) injections of low doses of humanized anti-CD20 veltuzumab is active in chronic lymphocytic leukemia (CLL). ASH Annual Meeting Abstracts. 2012;120(21):192.

12.

Woyach JA, Awan F, Flinn IW, Enoch R, Foster PA, Byrd JC. Final results of a phase I study of the Fc engineered CD19 antibody XmAb(R)5574 (MOR00208) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ASH Annual Meeting Abstracts. 2012;120(21):2894.

13.

Forero A, Hamadani M, Fanale MA, Bello CM, Kipps TJ, Offner F, et al. MEDI-551, a humanized monoclonal anti-CD19, in adults with relapsed or refractory advanced B-cell malignancies: results from a phase 1/2 study. ASH Annual Meeting Abstracts. 2012;120(21):3677.

14.

Matas-Cespedes A, Vidal-Crespo A, Rodriguez V, Roue G, Campo E, Colomer D, et al. Daratumumab, a novel human anti-CD38 monoclonal antibody for the treatment of chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma. ASH Annual Meeting Abstracts. 2012;120(21):3935.

15.

Hellqvist E, Wu CCN, Widhopf GF, II, Shih A, Tawatao R, Lao F, et al. Selective clearance of chronic lymphocytic leukemia cells in vivo following treatment with UC99961, an anti-ROR1 monoclonal antibody. ASH Annual Meeting Abstracts. 2012;120(21):3886.

16.

Fischer K, Bahlo J, Fink A-M, Busch R, Bottcher S, Mayer J, et al. Extended follow up of the CLL8 protocol, a randomized phase-III trial of the German CLL study group (GCLLSG) comparing fludarabine and cyclophosphamide (FC) to FC plus rituximab (FCR) for previously untreated patients with chronic lymphocytic leukemia (CLL): results on survival, progression-free survival, delayed neutropenias and secondary malignancies confirm superiority of the FCR regimen. ASH Annual Meeting Abstracts. 2012;120(21):435.

17.

Dartigeas C, Van Den Neste E, Berthou C, Maisonneuve H, Lepretre S, Dilhuydy M-S, et al. Safety and efficacy of abbreviated induction with oral fludarabine (F) and cyclophosphamide (C) combined with dose-dense IV rituximab (R) in previously untreated patients with chronic lymphocytic leukemia (CLL) Aged > 65 years: results of a multicenter trial (LLC 2007 SA) on behalf of the French Goelams/Fcgcll-WM intergroup. ASH Annual Meeting Abstracts. 2012;120(21):434.

18.

Mulligan SP, Gill DS, Turner P, Renwick WEP, Harrup R, Latimer M, et al. A randomised dose de-escalation safety study of oral fludarabine, ± oral cyclophosphamide and intravenous rituximab (OFOCIR) as first-line therapy of fit patients with chronic lymphocytic leukaemia (CLL) Aged ≥ 65 years—end of recruitment analysis of response and toxicity of the Australasian leukaemia and lymphoma group (ALLG) and CLL Australian research consortium (CLLARC) CLL5 study. ASH Annual Meeting Abstracts. 2012;120(21):436.

19.

Wierda WG, Balakrishnan K, Ferrajoli A, O’Brien S, Burger JA, Kadia TM, et al. Fludarabine, bendamustine, and rituximab (FBR) chemoimmunotherapy is a safe and active regimen for relapsed/refractory CLL with in vivo mechanism of action for combination chemotherapy. ASH Annual Meeting Abstracts. 2012;120(21):437.

20.

Flinn IW, Cooper RS, Thompson DS, Waselenko JK, Reeves J Jr., Wise RL, et al. Fludarabine, rituximab, and lenalidomide in previously untreated patients with chronic lymphocytic leukemia (CLL): a phase I/II trial of the Sarah cannon research institute. ASH Annual Meeting Abstracts. 2012;120(21):715.

21.

Awan F, Jaeger U, Rifkin R, Thirman MJ, Byrd JC, Hallek M, et al. Phase 1b study of TRU-016, an anti-CD37 SMIP & trade; protein, in combination with bendamustine vs bendamustine alone in relapsed chronic lymphocytic leukemia. ASH Annual Meeting Abstracts. 2012;120(21):1795.

22.

Egle A, Steurer M, Gassner F, Geisberger R, Melchardt T, Weiss L, et al. A combination of fludarabine/rituximab with escalating doses of lenalidomide in previously untreated chronic lymphocytic leukemia (CLL): the REVLIRIT CLL5 AGMT phase I/II study, clinical and exploratory analyses of induction results. ASH Annual Meeting Abstracts. 2011;118(21):292.

Titel: ASH 2012 update chronic lymphocytic leukemia—the best is yet to come
verfasst von: Lukas Weiss
Thomas Melchardt
Richard Greil
Georg Hopfinger
Publikationsdatum: 01.09.2013
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 3/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-013-0099-3

Springer Medizin Österreich

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2013

Molecular therapies of colorectal cancer: where will we go from here?

What’s new in Hodgkin’s lymphoma: ASH 2012 and more

Philadelphia-negative myeloproliferative neoplasms at the 2012 ASH meeting: a personal summary

Georgia on my mind: multiple myeloma highlights at ASH 2012

Biosimilars versus generics: scientific basics and clinical implications

ASH 2012: “Helping hematologists conquer blood diseases worldwide”